Table 5.
Number of DLTs
| AEs | Statistics from individual study (DLT number) | Tatal number | |||||
|---|---|---|---|---|---|---|---|
| 2† (Ganitumab) ‡ | 3 (CIX and Torisel) | 7 (dalotuzumab) | 8 (Erlotinib and CIX) | 10 (CP and CB and PAC) | 11 (CIX) | ||
| Thrombocytopenia | 2 | 1 | 1 | 1 | 5 | ||
| Fatigue | 4 | 4 | |||||
| Acneiform rash | 3 | 3 | |||||
| Febrile neutropenia | 1 | 1 | |||||
| Leukocytoclastic vasculitis | 1 | 1 | |||||
| Hyperuricaemia | *1 | 1 | |||||
| Hypermagnesaemia | *1 | 1 | |||||
| Hyponatraemia | *1 | 1 | |||||
| Hyperkalaemia | *1 | 1 | |||||
| Dehydration | 1 | 1 | |||||
*
DLT observed in the same patient;
†
study number;
‡
drugs. CB, carboplatin; CIX, cixutumumab; CP, figitumumab; DLT, dose-limited toxicities; PAC, paclitaxel; Torisel, temsirolimus.